2025
Cerebrospinal fluid immune phenotyping reveals distinct immunotypes of myalgic encephalomyelitis/chronic fatigue syndrome.
Bastos V, Greene K, Tabachnikova A, Bhattacharjee B, Sjögren P, Bertilson B, Reifert J, Zhang M, Kamath K, Shon J, Gehlhausen J, Guan L, VanElzakker M, Proal A, Bragée B, Iwasaki A. Cerebrospinal fluid immune phenotyping reveals distinct immunotypes of myalgic encephalomyelitis/chronic fatigue syndrome. The Journal Of Immunology 2025 PMID: 40373264, DOI: 10.1093/jimmun/vkaf087.Peer-Reviewed Original ResearchMyalgic encephalomyelitis/chronic fatigue syndromeCerebrospinal fluidImmune phenotypeFatigue syndromeMatched healthy control subjectsAssessed plasma samplesMultiplex analysis of cytokinesHealthy control subjectsAnalysis of cerebrospinal fluidAnalysis of cytokinesTreatment developmentClinical presentationSymptom presentationMultiorgan diseaseInflammatory profileControl subjectsPathophysiological mechanismsMatrix metalloproteinase profilesDisease subgroupsME/CFS participantsClinical questionnaireMatrix metalloproteinasesMetalloproteinase profilesHigh-throughput microarrayPlasma samplesPrenatal opioid exposure alters pain perception and increases long-term health risks in infants with neonatal opioid withdrawal syndrome
Radhakrishna U, Radhakrishnan R, Uppala L, Trivedi T, Prajapati J, Rawal R, Muvvala S, Bahado-Singh R, Sadhasivam S. Prenatal opioid exposure alters pain perception and increases long-term health risks in infants with neonatal opioid withdrawal syndrome. Frontiers In Pain Research 2025, 6: 1497801. PMID: 40313396, PMCID: PMC12043715, DOI: 10.3389/fpain.2025.1497801.Peer-Reviewed Original ResearchNeonatal opioid withdrawal syndromeOpioid-exposed infantsOpioid withdrawal syndromePain-related genesOpioid exposureWithdrawal syndromeChronic painEpigenetic changesMaternal opioid exposurePrenatal opioid exposureImprove pain managementIon channel functionIllumina Infinium Methylation EPIC BeadChipInfinium Methylation EPIC BeadChipAnalyzed DNA methylationUnexposed control subjectsLong-term health risksPain reliefPain perceptionPregnant womenGnRH secretionPlacental tissueMorphine addictionHealth of mothersControl subjectsImmune dysregulation in glycogen storage disease 1b extends beyond neutropenia
Gehlhaar A, Shouval D, Santiago E, Ling G, McCourt B, Werner L, Yerushalmi B, Konnikova L. Immune dysregulation in glycogen storage disease 1b extends beyond neutropenia. Human Immunology 2025, 86: 111268. PMID: 40037121, DOI: 10.1016/j.humimm.2025.111268.Peer-Reviewed Original ResearchGlycogen storage disease type 1bGlycogen storage disease type 1b patientsImpaired immune cell traffickingClassic treatment strategiesUpregulation of CXCR3Effector memory phenotypeT cell populationsNatural killer cellsSystems immunology approachNon-classical monocytesImmune cell traffickingGlycogen storage disease 1bImmune defectsMemory phenotypeMultiple T cell populationsImmune landscapeRecurrent infectionsKiller cellsImmune dysregulationImmune impairmentImmunophenotypic characterizationSLC37A4 geneControl subjectsTreatment strategiesNeutrophil numbersFGF21 Signaling Exerts Antifibrotic Properties during Pulmonary Fibrosis.
Ghanem M, Archer G, Justet A, Jaillet M, Vasarmidi E, Mordant P, Castier Y, Mal H, Cazes A, Poté N, Crestani B, Mailleux A. FGF21 Signaling Exerts Antifibrotic Properties during Pulmonary Fibrosis. American Journal Of Respiratory And Critical Care Medicine 2025, 211: 486-498. PMID: 39637324, DOI: 10.1164/rccm.202311-2021oc.Peer-Reviewed Original ResearchConceptsIdiopathic pulmonary fibrosisWild-type littermatesPlasma of patientsPulmonary fibrosisAntifibrotic propertiesIntratracheal injection of bleomycinDevelopment of pulmonary fibrosisDecreased fibrosis markersEffects of FGF21Increased sensitivity to bleomycinInjection of bleomycinPulmonary fibrosis developmentSensitivity to bleomycinDecrease of BaxConcentrations of FGF21Human lung fibroblastsTherapeutic optionsFibrosis markersAntifibrotic effectsControl subjectsInjury scoreIntratracheal injectionLiver fibrosisLung fibrogenesisFibroblast growth factorDistinctive Macrophage Migration Inhibitory Factor Receptor Patterns and Soluble Biomarkers in Rheumatoid Arthritis: Unveiling Key Associations with Disease Activity
Sánchez-Zuno G, Bucala R, Hernández-Bello J, Palafox-Sánchez C, Vizcaíno-Quirarte A, Muñoz-Valle J. Distinctive Macrophage Migration Inhibitory Factor Receptor Patterns and Soluble Biomarkers in Rheumatoid Arthritis: Unveiling Key Associations with Disease Activity. Journal Of Interferon & Cytokine Research 2025, 45: 99-106. PMID: 39914814, PMCID: PMC12021775, DOI: 10.1089/jir.2024.0184.Peer-Reviewed Original ResearchConceptsMigration inhibitory factorMigration inhibitory factor levelsDisease activityRA patientsControl subjectsRheumatoid arthritisLevels of migration inhibitory factorSerum levels of CXCL12Levels of CXCL12Serum of RA patientsModerate disease activityMembranous expression patternRheumatoid factor titerMIF levelsCXCL12 levelsSerum levelsCXCL8 levelsSoluble biomarkersTreatment protocolsPattern of expressionSerum CXCL8PatientsReceptor patternsClinical biomarkersInhibitory factorTSC-100 and TSC-101 Demonstrate the Potential to Reduce Relapse Rates and Increase Relapse-Free Survival in Patients with AML, ALL, or MDS Undergoing Allogeneic Hematopoietic Cell Transplantation (HCT) with Reduced Intensity Conditioning (RIC): Preliminary Results from the Phase 1 Alloha Trial (NCT05473910)
Al Malki M, Keyzner A, Popat U, Chen Y, Suh H, Jain T, Solh M, Snow A, Pineiro L, Gill S, Gowda L, Uberti J, White T, Wang Y, Nguyen C, Louis C, Chattopadhyay S, Matzko M, Reshef R. TSC-100 and TSC-101 Demonstrate the Potential to Reduce Relapse Rates and Increase Relapse-Free Survival in Patients with AML, ALL, or MDS Undergoing Allogeneic Hematopoietic Cell Transplantation (HCT) with Reduced Intensity Conditioning (RIC): Preliminary Results from the Phase 1 Alloha Trial (NCT05473910). Transplantation And Cellular Therapy 2025, 31: s59-s60. DOI: 10.1016/j.jtct.2025.01.096.Peer-Reviewed Original ResearchRIC HCTReduced intensity conditioningHematopoietic cell transplantationRelapse-free survivalPost-HCTControl subjectsControl armDonor chimerismGrade II-IV acute graft-versus-host diseaseII-IV acute graft-versus-host diseaseT cell receptor-engineered T cellsAcute graft-versus-host diseasePhase 1 dose-escalation studyIncreased relapse-free survivalGraft-versus-host diseaseAllogeneic hematopoietic cell transplantationNon-relapse deathPost-HCT MRDEngineered T cellsCytokine release syndromeData cut-offMonths post-HCTReducing relapse ratesYears post-HCTAssessment of efficacyPtpA protein from Mycobacterium avium subsp. paratuberculosis as a potential marker of rheumatoid arthritis in humans
Hernández-Bello J, Bach H, Cerpa-Cruz S, Sánchez-Zuno G, Hernández-Gutiérrez R, Nicoletti F, Saraceno A, Muñoz-Valle J. PtpA protein from Mycobacterium avium subsp. paratuberculosis as a potential marker of rheumatoid arthritis in humans. PLOS ONE 2025, 20: e0316727. PMID: 39752467, PMCID: PMC11698356, DOI: 10.1371/journal.pone.0316727.Peer-Reviewed Original ResearchConceptsMycobacterium avium subspecies paratuberculosisControl subjectsVirulence factorsRA patientsBattery of virulence factorsRheumatoid arthritisProtein tyrosine phosphatase ADisease activityPhago-lysosome fusionModerate to high disease activityHigh disease activityDisease Activity ScoreMale control subjectsIndirect ELISA methodMycobacterium avium subspecies paratuberculosis infectionMycobacterium avium subspPhosphatase AMarkers of rheumatoid arthritisIntracellular pathogensPTPAMedian ODActivity scoreProteinELISA methodPatientsDepth inversion illusion and its relationship to positive symptoms in clinical and non-clinical voice hearers
Erickson M, Li C, Bansal S, Waltz J, Corlett P, Gold J. Depth inversion illusion and its relationship to positive symptoms in clinical and non-clinical voice hearers. Cognitive Neuropsychiatry 2025, 30: 31-42. PMID: 39969991, PMCID: PMC12033074, DOI: 10.1080/13546805.2025.2467974.Peer-Reviewed Original ResearchPositive symptomsHealthy control subjectsAssociated with positive symptomsEnhanced perception of stimuliDepth inversion illusionsNon-clinical voice hearersVisual illusionsPerception of stimuliIllusion taskSymptom severityModulation of sensory informationPsychiatric illnessInversion illusionsIllusion perceptionVoice hearersMental illnessEnhanced perceptionSensory informationSymptomsControl subjectsPSZIllnessIllusionSchizophreniaDelusions
2024
Application of digital tools and artificial intelligence in the Myasthenia Gravis Core Examination
Garbey M, Lesport Q, Girma H, Öztosun G, Abu-Rub M, Guidon A, Juel V, Nowak R, Soliven B, Aban I, Kaminski H. Application of digital tools and artificial intelligence in the Myasthenia Gravis Core Examination. Frontiers In Neurology 2024, 15: 1474884. PMID: 39697445, PMCID: PMC11652356, DOI: 10.3389/fneur.2024.1474884.Peer-Reviewed Original ResearchNatural language processingMyasthenia gravisArtificial intelligenceArtificial intelligence methodsSeries of algorithmsComputer visionSignal processing methodsExamination of patientsConventional clinical settingsLanguage processingIntelligence methodsNon-physician healthcare providersVideoControl subjectsClinical trialsPatientsRespiratory metricsMyastheniaBreath countClinical settingAlgorithmBody motionVideos of patientsTelemedicine evaluationIntelligenceA Method for Multimodal IVA Fusion Within a MISA Unified Model Reveals Markers of Age, Sex, Cognition, and Schizophrenia in Large Neuroimaging Studies
Silva R, Damaraju E, Li X, Kochunov P, Ford J, Mathalon D, Turner J, van Erp T, Adali T, Calhoun V. A Method for Multimodal IVA Fusion Within a MISA Unified Model Reveals Markers of Age, Sex, Cognition, and Schizophrenia in Large Neuroimaging Studies. Human Brain Mapping 2024, 45: e70037. PMID: 39560198, PMCID: PMC11574741, DOI: 10.1002/hbm.70037.Peer-Reviewed Original ResearchConceptsMultimodal neuroimaging datasetSchizophrenia patientsNeuroimaging studiesCognitive performanceGroup differencesSchizophreniaSex effectsNeuroimaging datasetsMagnetic resonance imagingCognitionAge-associated declineControl subjectsMarkers of agingResonance imagingNon-imaging variablesSubject profilesSexNeuroimagingUK Biobank datasetTSC-100 and TSC-101 Demonstrate the Potential to Reduce Relapse Rates and Increase Relapse-Free Survival in Patients with AML, ALL, or MDS Undergoing Allogeneic HCT with Reduced Intensity Conditioning (RIC): Preliminary Results from the Phase 1 Alloha Trial
Al Malki M, Keyzner A, Popat U, Chen Y, Suh H, Jain T, Solh M, Snow A, Gill S, Gowda L, Uberti J, Buonomo E, Wang Y, Nabilsi N, White T, Nguyen C, Murray J, MacBeath G, Louis C, Chattopadhyay S, Matzko M, Reshef R. TSC-100 and TSC-101 Demonstrate the Potential to Reduce Relapse Rates and Increase Relapse-Free Survival in Patients with AML, ALL, or MDS Undergoing Allogeneic HCT with Reduced Intensity Conditioning (RIC): Preliminary Results from the Phase 1 Alloha Trial. Blood 2024, 144: 924. DOI: 10.1182/blood-2024-201526.Peer-Reviewed Original ResearchReduced intensity conditioningRelapse-free survivalPost-HCTDonor chimerismTreatment armsFollow-upControl armMalignant lineagesGrade 2-4 acute graft-versus-host diseaseT cell receptor-engineered T cellsControl subjectsIncreased relapse-free survivalGraft-versus-host diseaseMedian time to relapseControl arm subjectsNon-relapse deathPost-HCT MRDComplete donor chimerismDonor-derived cellsEngineered T cellsMedian Follow-UpTime to relapseCD3+ cellsPhase 1 studyARMS subjectsDetection of hepatocellular carcinoma methylation markers in salivary DNA
Mezzacappa C, Wang Z, Lu L, Risch H, Taddei T, Yu H. Detection of hepatocellular carcinoma methylation markers in salivary DNA. Bioscience Reports 2024, 44: bsr20232063. PMID: 38457142, PMCID: PMC10958141, DOI: 10.1042/bsr20232063.Peer-Reviewed Original ResearchHepatocellular carcinoma screeningCase patientsHepatocellular carcinomaControl subjectsDiagnosis of hepatocellular carcinomaAssociated with hepatocellular carcinomaScreening testSalivary DNASaliva-based testCpG sitesStudy of risk factorsSalivary DNA methylationDNA methylationViral hepatitisCirculating DNAAlterations to DNA methylationRisk factorsMethylation markersPatientsRegulation of cell cycle progressionBlood samplesCell cycle progressionAffected individualsAlternative to blood samplingMultiple comparisonsTaste and smell function in Wilson's disease
Salmon M, Cohen W, Hu F, Aydin A, Coskun A, Schilsky M, Doty R. Taste and smell function in Wilson's disease. Journal Of The Neurological Sciences 2024, 459: 122949. PMID: 38493734, DOI: 10.1016/j.jns.2024.122949.Peer-Reviewed Original ResearchWilson's diseaseSmell functionUniversity of Pennsylvania Smell Identification TestPennsylvania Smell Identification TestSmell test scoresSmell Identification TestAbnormal copper metabolismOlfactory dysfunctionWD patientsOlfactory functionNeurological symptomsControl subjectsPrimary medicationTaste functionPathophysiological mechanismsHealthy controlsLinear regression analysisMultiple linear regression analysisIdentification TestCopper metabolismPatientsNO effectTaste testRegression analysisDiseaseExpression of Transcriptional Factors of T Helper Differentiation (T-bet, GATA-3, RORγt, and FOXP3), MIF Receptors (CD44, CD74, CXCR2, 4, 7), and Th1, Th2, and Th17 Cytokines in PBMC from Control Subjects and Rheumatoid Arthritis Patients
Zerpa-Hernández D, García-Chagollán M, Sánchez-Zuno G, García-Arellano S, Hernández-Bello J, Hernández-Palma L, Cerpa-Cruz S, Martinez-Bonilla G, Nicoletti F, Muñoz-Valle J. Expression of Transcriptional Factors of T Helper Differentiation (T-bet, GATA-3, RORγt, and FOXP3), MIF Receptors (CD44, CD74, CXCR2, 4, 7), and Th1, Th2, and Th17 Cytokines in PBMC from Control Subjects and Rheumatoid Arthritis Patients. 2024, 24: 1169-1182. PMID: 37807647, DOI: 10.2174/0115665240260976230925095330.Peer-Reviewed Original ResearchConceptsPeripheral blood mononuclear cellsMacrophage migration inhibitory factorT CD4+ lymphocytesMIF receptorRA patientsControl subjectsCS groupTh17 cytokinesRheumatoid arthritisElevated levels of pro-inflammatory cytokinesActivity of Foxp3Multiplex bead analysisLevels of pro-inflammatory cytokinesExpression of CXCR7Expression of CD74Expression of GATA3Levels of cytokinesT helper differentiationBlood mononuclear cellsPro-inflammatory cytokinesMigration inhibitory factorDevelopment of rheumatoid arthritisRheumatoid arthritis patientsProfile cytokinesTh17 responses
2023
Patients With Cystic Fibrosis Undergoing Total Hip and Total Knee Arthroplasty Are at Increased Risk for Perioperative Complications
Halperin S, Dhodapkar M, Radford Z, Kaszuba S, Rubin L, Grauer J. Patients With Cystic Fibrosis Undergoing Total Hip and Total Knee Arthroplasty Are at Increased Risk for Perioperative Complications. Journal Of The American Academy Of Orthopaedic Surgeons 2023, 32: 309-315. PMID: 38165956, DOI: 10.5435/jaaos-d-23-00783.Peer-Reviewed Original ResearchTotal knee arthroplastyTotal hip arthroplastyUrinary tract infectionPostoperative eventsCystic fibrosisPerioperative outcomesAdverse eventsTract infectionsPleural effusionKnee arthroplastyControl subjectsRevision rateAcute kidney injuryElixhauser Comorbidity IndexRisk of surgeryMultivariable logistic regressionComorbidity indexKidney injuryPerioperative complicationsRespiratory failureTKA patientsCardiac eventsPearlDiver databaseImplant survivalTotal hipAnandamide and 2-arachidonoylglycerol baseline plasma concentrations and their clinical correlate in gambling disorder
Baenas I, Solé-Morata N, Granero R, Fernández-Aranda F, Pujadas M, Mora-Maltas B, Lucas I, Gómez-Peña M, Moragas L, del Pino-Gutiérrez A, Tapia J, de la Torre R, Potenza M, Jiménez-Murcia S. Anandamide and 2-arachidonoylglycerol baseline plasma concentrations and their clinical correlate in gambling disorder. European Psychiatry 2023, 66: e97. PMID: 37937379, PMCID: PMC10755577, DOI: 10.1192/j.eurpsy.2023.2460.Peer-Reviewed Original ResearchConceptsHealthy control subjectsPlasma concentrationsBaseline plasma concentrationsPeripheral blood samplesBrain reward pathwaysGambling disorderSemi-structured clinical interviewConcentrations of endocannabinoidsNeuropsychological variablesAddiction-related disordersGD severityClinical correlatesControl subjectsAdult outpatientsEndocannabinoid systemBlood samplesClinical InterviewPlasma AEA concentrationsEndogenous ligandReward pathwayClinical groupsEndocannabinoidsAEA concentrationsPsychometric assessmentNeurobiological substratesCirculating Levels of Leptin and Lipocalin-2 in Patients With X-Linked Hypophosphatemia
Simpson C, Santoro A, Carpenter T, Deng Y, Parziale S, Insogna K. Circulating Levels of Leptin and Lipocalin-2 in Patients With X-Linked Hypophosphatemia. Journal Of The Endocrine Society 2023, 7: bvad116. PMID: 37860221, PMCID: PMC10583534, DOI: 10.1210/jendso/bvad116.Peer-Reviewed Original ResearchLipocalin-2Control subjectsGreater riskLevels of LCN2Excessive weight gainLevels of leptinSerum leptin levelsCirculating LevelsLCN2 levelsSerum levelsYear age cohortLeptin levelsMetabolic abnormalitiesRetrospective studyAge cohortsInsulin sensitivityHigh prevalencePatientsWeight gainXLHLeptinAge 2HypophosphatemiaObesityChildrenPulmonary artery wave intensity analysis in a pig model of lung resection
KEAST T, GLASS A, MCCALL P, SHELLEY B, HEERDT P. Pulmonary artery wave intensity analysis in a pig model of lung resection. Journal Of Cardiothoracic And Vascular Anesthesia 2023, 37: 9-10. DOI: 10.1053/j.jvca.2023.08.023.Peer-Reviewed Original ResearchForward compression waveBackward compression waveWave intensity analysisControl subjectsLung resectionPulmonary arteryPig modelSystolic timeCardiovascular MRIInvasive haemodynamic dataPulmonary artery pressureRight ventricular functionProximal pulmonary arteriesMain pulmonary arteryPost-operative patientsRight ventricular contractionWave reflection indicesMann-Whitney testIncreased afterloadLabChart softwareArtery pressureHaemodynamic effectsRV functionUpper lobectomyVentricular functionPatent Ductus Arteriosus and Development of Bronchopulmonary Dysplasia-associated Pulmonary Hypertension.
Gentle S, Travers C, Clark M, Carlo W, Ambalavanan N. Patent Ductus Arteriosus and Development of Bronchopulmonary Dysplasia-associated Pulmonary Hypertension. American Journal Of Respiratory And Critical Care Medicine 2023, 207: 921-928. PMID: 36378949, PMCID: PMC10111998, DOI: 10.1164/rccm.202203-0570oc.Peer-Reviewed Original ResearchConceptsBPD-associated pulmonary hypertensionPatent ductus arteriosusDuctus arteriosus patencyPreterm infantsBronchopulmonary dysplasiaPostnatal dayDuctus arteriosusPulmonary hypertensionRespiratory supportModerate to large patent ductus arteriosusBronchopulmonary dysplasia-associated pulmonary hypertensionPreterm infants of gestational ageInfants of gestational ageRetrospective case-control studyEvolving bronchopulmonary dysplasiaExtremely preterm infantsCase-control studyModifiable risk factorsGestational ageDuctal patencyComposite outcomeControl subjectsRisk factorsInfantsPatencyIntermittent Hypoxemia and Bronchopulmonary Dysplasia with Pulmonary Hypertension in Preterm Infants.
Gentle S, Travers C, Nakhmani A, Indic P, Carlo W, Ambalavanan N. Intermittent Hypoxemia and Bronchopulmonary Dysplasia with Pulmonary Hypertension in Preterm Infants. American Journal Of Respiratory And Critical Care Medicine 2023, 207: 899-907. PMID: 36449386, PMCID: PMC10111996, DOI: 10.1164/rccm.202203-0580oc.Peer-Reviewed Original ResearchConceptsBronchopulmonary dysplasia-associated pulmonary hypertensionIntermittent hypoxemiaHypoxemic eventsReceiver Operating CharacteristicPreterm infantsPulmonary hypertensionControl subjectsWeeks 6 daysExtremely preterm infantsWeeks 0 daysHigher risk of deathIdentification of infantsCase-control studyRisk of deathBronchopulmonary dysplasiaDesaturation frequencyEchocardiographic dataPostnatal dayBedside biomarkersIH eventsHigh riskInfantsHypoxemiaHypertensionLong duration
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply